Navigation Links
Targeted prostate biopsy has potential to improve diagnosis of prostate cancer
Date:12/10/2012

New York, NY, December 10, 2012 Diagnosis of prostate cancer remains imperfect. Current methods of prostate biopsy are limited by over detection of slow-growing tumors and under detection of clinically relevant cancers. Investigators at the University of California-Los Angeles Department of Urology have found that a new technique of targeted biopsy in a clinic setting, using local anesthesia, may improve diagnosis and aid in selecting which patients are suitable for active surveillance and which need focal therapy (noninvasive techniques for destroying small tumors within the prostate). Their results are published in The Journal of Urology.

"The technology exists to biopsy prostate tumors under magnetic resonance imaging (MRI) guidance and this has been shown to improve prostate cancer diagnosis," says first author Geoffrey Sonn, MD, Department of Urology, Institute of Urologic Oncology, University of California-Los Angeles. "But such procedures are time-consuming, costly, and impractical in most settings. Magnetic resonance ultrasound (MR-US) systems that fuse stored MR images with real-time ultrasound combine the resolution of MRI with the ease and practicality of ultrasound, offering a savings in time and cost, while potentially retaining the accuracy of MR-guided biopsy. However there are further limiting factors the need for monitored anesthesia care, or a transperineal approach and general anesthesia."

Investigators report on the findings in a group of men who underwent MR-US fusion biopsy as outpatients at the UCLA Clark Urology Center. Of the 171 men in the study, 106 underwent biopsy for surveillance, while 65 had an increased prostate specific antigen (PSA) level but previously negative biopsies. All had a median PSA of 4.9 ng/ml and a median prostate size of 48 cc. Following a procedure lasting about 20 minutes, none of the patients required hospitalization.

The researchers found that a targeted biopsy was three times more likely to identify cancer than a systematic biopsy. The biopsies showed prostate cancer in 90 of the 171 men.

"The study yielded three key findings," reports Leonard S. Marks, MD, lead investigator, professor of urology and director of the UCLA Active Surveillance Program. "First, it demonstrated the ability to target and biopsy lesions in an office-based setting with the patient under local anesthesia. Second, adding targeted biopsies to systematic biopsies increased the rate of diagnosis of all cancers and, more importantly, Gleason 7 or greater cancer. In fact, 38% of men with Gleason 7 or greater cancer had disease which was detected only by targeted biopsies of lesions detected on MRI. Third, the level of suspicion on MRI correlates with cancer diagnosis overall and diagnosis of Gleason 7 or greater prostate cancers. The biopsies revealed prostate cancer in 16 of 17 men with a grade 5 lesion on MRI."

The study shows that targeted prostate biopsy may be useful in the three key situations of active surveillance, increased PSA but negative transrectal ultrasound (TRUS) biopsy, and selection for focal therapy. It may improve patient selection, making surveillance a more attractive option for patients while reducing progression to active treatment. It may also identify tumors missed on TRUS biopsy, sparing patients the discomfort of numerous negative biopsies and reducing the risk of delayed diagnosis of aggressive tumors.

"Finally, focal therapy has become an area of keen interest. This technique can spare patients the more invasive, morbid perineal template-mapping biopsy often required for focal therapy. Two recent studies using different MR-US fusion devices yielded similar results. "This substantiates the advantages of image-guided targeted biopsy using MR-US fusion" concludes Dr. Marks.

The investigators acknowledge that due to the low risk patient population studied, relatively few patients underwent radical prostate surgery. "It remains possible that some tumors may be missed by this technique," says Dr. Marks. Further work, including a detailed study correlating MRI, targeted biopsy results, and prostatectomy specimens is ongoing.

Commenting on the study, Dr. Bradford Hood and colleagues at the National Cancer Institute, NIH, write, "MR-US fusion guided biopsy unblinds the 'blind' biopsy and has great potential to supplement or replace 'blind' TRUS prostate biopsies. However, significant hurdles remain to broad adoption and the best approach is yet to be determined."


'/>"/>

Contact: Linda Gruner
jumedia@elsevier.com
212-633-3923
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Targeted Prostate Cancer Biopsies Might Improve Care: Study
2. Researchers report first success of targeted therapy in most common non-small cell lung cancer
3. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
4. Temple researchers show targeted cancer drug may stunt hearts ability to repair itself
5. Large lung cancer study shows potential for more targeted therapies
6. Deadly witch hunts targeted by grassroots womens groups
7. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Lower risk of serious side-effects in trials of new targeted drugs
10. Killer infections targeted by hospital study
11. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: